Agilent Technologies, Inc. $A Shares Acquired by Jennison Associates LLC

Key Points

• Jennison Associates increased its Agilent Technologies stake by 81.3% in the second quarter, adding 278,571 shares to own 621,278 shares valued at approximately $82.5 million.
• Agilent reported quarterly EPS of $1.49, beating estimates of $1.41, while revenue rose 10% year over year to $1.83 billion. The company guided for fiscal 2026 EPS of $6.00–$6.10.
• The stock recently traded at $148.55, while analysts maintained a “Moderate Buy” consensus rating with an average price target of $160.24; Agilent also pays a quarterly dividend of $0.255 per share.

Jennison Associates LLC increased its holdings in shares of Agilent Technologies, Inc. (NYSE:A - Free Report) by 81.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 621,278 shares of the medical research company's stock after buying an additional 278,571 shares during the period. Jennison Associates LLC owned about 0.22% of Agilent Technologies worth $82,524,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently added to or reduced their stakes in the company. Eurizon SLJ Capital Ltd acquired a new position in Agilent Technologies during the second quarter worth $10,128,000. Hohimer Wealth Management LLC grew its position in shares of Agilent Technologies by 4.6% in the second quarter. Hohimer Wealth Management LLC now owns 5,470 shares of the medical research company's stock valued at $727,000 after purchasing an additional 239 shares during the period. Avidian Wealth Enterprises LLC grew its position in shares of Agilent Technologies by 9.3% in the second quarter. Avidian Wealth Enterprises LLC now owns 7,318 shares of the medical research company's stock valued at $972,000 after purchasing an additional 623 shares during the period. KPP Advisory Services LLC increased its stake in shares of Agilent Technologies by 2.4% during the second quarter. KPP Advisory Services LLC now owns 4,382 shares of the medical research company's stock worth $582,000 after purchasing an additional 103 shares in the last quarter. Finally, Vest Financial LLC purchased a new stake in shares of Agilent Technologies during the second quarter worth about $385,000.

Agilent Technologies Stock Performance

NYSE:A opened at $148.55 on Friday. The company has a market cap of $41.95 billion, a P/E ratio of 29.83, a P/E/G ratio of 2.64 and a beta of 1.25. Agilent Technologies, Inc. has a twelve month low of $108.35 and a twelve month high of $160.27. The company's 50-day moving average price is $135.38 and its 200-day moving average price is $125.56. The company has a current ratio of 2.10, a quick ratio of 1.62 and a debt-to-equity ratio of 0.43.

Agilent Technologies (NYSE:A - Get Free Report) last announced its quarterly earnings data on Wednesday, May 27th. The medical research company reported $1.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.41 by $0.08. The company had revenue of $1.83 billion during the quarter, compared to analysts' expectations of $1.80 billion. Agilent Technologies had a net margin of 19.55% and a return on equity of 24.33%. Agilent Technologies's revenue was up 10.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.31 EPS. Agilent Technologies has set its FY 2026 guidance at 6.000-6.100 EPS and its Q3 2026 guidance at 1.480-1.500 EPS. On average, sell-side analysts forecast that Agilent Technologies, Inc. will post 6.03 earnings per share for the current fiscal year.

Agilent Technologies Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, July 22nd. Stockholders of record on Tuesday, June 30th were issued a dividend of $0.255 per share. This represents a $1.02 annualized dividend and a dividend yield of 0.7%. The ex-dividend date was Tuesday, June 30th. Agilent Technologies's payout ratio is currently 20.48%.

Wall Street Analysts Forecast Growth

A has been the subject of several research analyst reports. Sanford C. Bernstein assumed coverage on shares of Agilent Technologies in a research report on Friday, June 26th. They set an "outperform" rating and a $155.00 price target for the company. Royal Bank Of Canada started coverage on Agilent Technologies in a report on Wednesday, May 27th. They issued an "outperform" rating and a $153.00 price objective on the stock. TD Cowen boosted their price objective on Agilent Technologies from $147.00 to $155.00 and gave the stock a "buy" rating in a research note on Thursday, May 28th. Jefferies Financial Group assumed coverage on Agilent Technologies in a report on Thursday, July 9th. They set a "hold" rating and a $135.00 target price for the company. Finally, Weiss Ratings upgraded Agilent Technologies from a "hold (c-)" rating to a "hold (c)" rating in a research report on Tuesday, June 2nd. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $160.24.

About Agilent Technologies

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company's product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source